NASDAQ:PDSB - PDS Biotechnology Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.60
  • Forecasted Upside: 289.41 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$5.29
▲ +0.2 (3.93%)

This chart shows the closing price for PDSB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PDS Biotechnology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PDSB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PDSB

Analyst Price Target is $20.60
▲ +289.41% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for PDS Biotechnology in the last 3 months. The average price target is $20.60, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 289.41% upside from the last price of $5.29.

This chart shows the closing price for PDSB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in PDS Biotechnology. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/25/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2022

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2022Alliance Global PartnersLower Price Target$18.00 ➝ $16.00Low
5/12/2022Noble FinancialReiterated RatingBuy$22.00Medium
10/22/2021Noble FinancialReiterated RatingBuy$23.00Low
8/12/2021HC WainwrightLower Price TargetBuy$20.00 ➝ $15.00Medium
7/7/2021Chardan CapitalReiterated RatingBuyHigh
6/28/2021Cantor FitzgeraldInitiated CoverageOverweight$25.00Medium
6/9/2021OppenheimerBoost Price TargetPositive ➝ Outperform$12.00 ➝ $25.00Low
6/9/2021Alliance Global PartnersBoost Price TargetBuy$6.50 ➝ $18.00Low
6/2/2021HC WainwrightBoost Price TargetBuy$8.00 ➝ $20.00Low
5/20/2021Chardan CapitalBoost Price TargetBuy$10.00 ➝ $11.00High
5/14/2021OppenheimerReiterated RatingBuyHigh
4/10/2021Chardan CapitalReiterated RatingBuy$10.00High
3/19/2021HC WainwrightBoost Price TargetBuy$6.00 ➝ $8.00Low
3/11/2021OppenheimerReiterated RatingBuy$7.00Medium
11/10/2020HC WainwrightUpgradeNeutral ➝ Buy$6.00Medium
10/6/2020Noble FinancialReiterated RatingBuy$6.60High
7/28/2020Alliance Global PartnersBoost Price TargetBuy$4.00 ➝ $6.50Medium
7/8/2020Chardan CapitalReiterated RatingBuy$10.00Medium
5/27/2020Alliance Global PartnersInitiated CoverageBuy$4.00Low
5/14/2020Noble FinancialReiterated RatingBuy$5.45Low
5/13/2020HC WainwrightReiterated RatingHoldMedium
4/30/2020HC WainwrightReiterated RatingHoldHigh
4/21/2020Noble FinancialReiterated RatingBuy$5.45Low
3/30/2020HC WainwrightDowngradeBuy ➝ Neutral$7.00Medium
3/9/2020Noble FinancialInitiated CoverageOutperform$5.45High
12/23/2019Chardan CapitalReiterated RatingBuy$10.00High
11/5/2019HC WainwrightInitiated CoverageBuy$7.00 ➝ $7.00High
10/23/2019Chardan CapitalInitiated CoverageBuy$10.00High
(Data available from 5/22/2017 forward)

News Sentiment Rating

-0.11 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
10/24/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
11/23/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/22/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
2/21/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 4 very negative mentions
3/23/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
4/22/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
5/22/2022

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
PDS Biotechnology logo
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
Read More

Today's Range

Now: $5.29
Low: $4.84
High: $5.30

50 Day Range

MA: $5.64
Low: $3.76
High: $6.68

52 Week Range

Now: $5.29
Low: $3.47
High: $17.85

Volume

385,741 shs

Average Volume

322,771 shs

Market Capitalization

$150.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.34

Frequently Asked Questions

What sell-side analysts currently cover shares of PDS Biotechnology?

The following Wall Street analysts have issued stock ratings on PDS Biotechnology in the last twelve months: Alliance Global Partners, Cantor Fitzgerald, Chardan Capital, HC Wainwright, Noble Financial, Oppenheimer Holdings Inc., StockNews.com, and Zacks Investment Research.
View the latest analyst ratings for PDSB.

What is the current price target for PDS Biotechnology?

0 Wall Street analysts have set twelve-month price targets for PDS Biotechnology in the last year. Their average twelve-month price target is $20.60, suggesting a possible upside of 289.4%.
View the latest price targets for PDSB.

What is the current consensus analyst rating for PDS Biotechnology?

PDS Biotechnology currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PDSB will outperform the market and that investors should add to their positions of PDS Biotechnology.
View the latest ratings for PDSB.

How do I contact PDS Biotechnology's investor relations team?

PDS Biotechnology's physical mailing address is 25B Vreeland Road, Florham Park NJ, 07932. The company's listed phone number is (800) 208-3343 and its investor relations email address is [email protected] The official website for PDS Biotechnology is www.pdsbiotech.com. Learn More about contacing PDS Biotechnology investor relations.